A month after besting rival Novo Nordisk A/S in a bidding war for obesity drug developer Metsera Inc., Pfizer Inc. is again adding to its GLP-1 arsenal, this time via a $2 billion licensing and collaboration agreement with Yaopharma, a subsidiary of China’s Fosun Pharmaceutical Co. Ltd.

Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Ayrmid, Incyte, Junshi, Ocular.

Biopharma happenings, including deals and partnerships, and other news in brief: Abeona, Abbvie, Ayrmid, Evotec, Kamada, OSE, Sandoz.

Clinical updates, including data readouts and publications: AL-S, Arcellx, Ascletis, Biomx, Cerevance, Deciphera, Disc, Dyne, Encoded, Galapagos, GRI, Immix, Innovent, Kymera, Neurona, Prime, Puretech, Sensorion, Star, Vivacta, Wave Life.

Biopharmas raising money in public or private financings, including: Blue Water, Immix, Kala, Medicus, Pan Cancer T.

New hires and promotions in the biopharma industry, including: Circular Genomics, Pepgen.

While the U.S. Congress has yet to address the artificial line it created between biosimilars and interchangeables when it passed the Biologics Price Competition and Innovation Act in 2010, the FDA is erasing that distinction for all practical purposes.

Relation Therapeutics Ltd. will collaborate with Novartis AG in a $1.7 billion deal to develop multiple programs to find and advance targets for treating atopic diseases caused by immune dysregulation. Novartis will pay Relation an up-front amount, an equity investment and R&D funding of $55 million. It’s the company’s second deal with big pharma in the past 12 months.